Cargando…

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Head and neck squamous cell carcinoma (HNSCC), in the locally advanced setting, relapses in more than 50% of cases after surgery and/or chemo-radiotherapy. Prognosis is then very poor with platinum-based chemotherapy yielding a median survival of 10 months and a 2-year survival rate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borel, Christian, Jung, Alain C., Burgy, Mickaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563963/ https://www.ncbi.nlm.nih.gov/pubmed/32967162 http://dx.doi.org/10.3390/cancers12092691

Ejemplares similares

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
por: Carinato, Hélène, et al.
Publicado: (2021)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma
por: Burgy, Mickaël, et al.
Publicado: (2021)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
por: Flanagan, Kevin C., et al.
Publicado: (2023)

Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Ghosh, Soma, et al.
Publicado: (2022)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021)

The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma
por: Salvestrini, Viola, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
por: Baa, Annie Kanchan, et al.
Publicado: (2023)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Efficacy and Safety of Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wu, Chunrong, et al.
Publicado: (2020)

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
por: Meliante, Piero Giuseppe, et al.
Publicado: (2023)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Plavc, Gaber, et al.
Publicado: (2020)

Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer
por: Abbas, Waseem, et al.
Publicado: (2021)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Peng, Ying-Peng, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck
por: Moudgil, Tarsem, et al.
Publicado: (2013)

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
por: Cristina, Valerie, et al.
Publicado: (2019)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Immunotherapy in head and neck squamous cell carcinoma: a narrative review
por: Sharon, Shay, et al.
Publicado: (2022)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40csg2u4vck1r7qvlulleeb8nr